Regeneron Pharmaceuticals increases stock buyback program by $3 billion

12 articles · Updated · MarketWatch · Apr 29

The board approved an additional $3 billion for buybacks, supplementing $688 million remaining as of March 31. Regeneron repurchased $803 million in stock in the first quarter.
The expanded buyback program reflects Regeneron's strong financial position, with a market capitalization exceeding $77 billion. The move is expected to enhance shareholder value and signal confidence in the company’s future.
Regeneron, based in Tarrytown, New York, continues to prioritize capital returns to shareholders amid robust performance in the biotechnology sector. No previous related buyback expansions were reported recently.

Is Regeneron's $3B buyback a sign of confidence or a lack of new investment ideas?

With a patent cliff looming, can Regeneron's pipeline deliver the next blockbuster drug in time?

Regeneron's new gene therapy is free, but is this a sustainable model for future genetic medicines?

How will Regeneron's new AI and patient data collaboration reshape its future drug discovery?

Can the new EYLEA HD fully offset the sales decline of its predecessor against rising competition?